AnalystsInsight

Charles Brennan (Jefferies): Analyst Track Record and Price‑Target Accuracy

How often Charles Brennan’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 29 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Charles Brennan ranks #772 of 1,121 analysts in Exent’s scoring (4.7★).
  • 52.4% of price targets were reached over 7 years, versus 53.6% for the average analyst.
  • Median time to reach a target: 99 days; 100.0% of calls were up 12 months later.
  • Most‑covered stocks: EPA-DSY, ETR-SAP, EPA-CAP, BME-AMS.
  • Free on Exent: Charles Brennan’s full record, with ratings 3 days after publication.

Charles Brennan’s track record at a glance

Charles Brennan of Jefferies ranks #772 of the 1,121 analysts Exent scores, with a 4.7★ rating and a focus on technology. Over a 7‑year lookback, 52.4% of Charles’s price targets were reached, 1.2 points below the 53.6% average across all analysts.

MetricCharles BrennanAll analysts
Price‑target hit rate52.4%53.6%
Median days to hit target99 days91 days
Calls up after 12 months100.0%64.6%
Median 12‑month return of calls+51.6%+13.4%
Hit rate, last 2 years0.0%—
Average worst drop after a call−6.1%—
Ratings in the sample29—
Stocks covered25—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetCharles Brennan
Under 30 days27.3%
30–90 days0.0%
90–180 days72.7%
Over 180 days0.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Charles Brennan covers most

StockRatings in the sample
EPA-DSY52
ETR-SAP49
EPA-CAP48
BME-AMS42
LON-CCC38
SWX-TEMN34
ETR-NEM32
LON-BYIT28

In the past year Charles’s ratings were 62% Buy, 24% Hold and 14% Sell.

Charles Brennan’s latest ratings

DateStockActionRatingPrice target
Oct 14, 2026LON-BYITReiterated: HoldHold$450.00
Oct 14, 2026LON-SCTReiterated: HoldHold$1700.00
Oct 1, 2026EPA-CAPReiterated: HoldHold$110.00
Sep 28, 2026EPA-DSYReiterated: SellSell$16.00
Sep 25, 2026EPA-DSYReiterated: SellSell$16.00
Sep 23, 2026ETR-NEMReiterated: BuyBuy$72.00
Sep 22, 2026SAPReiterated: BuyBuy$260.00
Sep 22, 2026ETR-SAPReiterated: BuyBuy$220.00
Sep 21, 2026LON-BYITReiterated: HoldHold$450.00
Sep 17, 2026LON-SCTReiterated: HoldHold$1700.00
Sep 17, 2026LON-BYITReiterated: HoldHold$370.00
Sep 8, 2026LON-CCCReiterated: BuyBuy$6500.00
  • Oct 14, 2026
    Stock
    LON-BYIT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $450.00
  • Oct 14, 2026
    Stock
    LON-SCT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $1700.00
  • Oct 1, 2026
    Stock
    EPA-CAP
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $110.00
  • Sep 28, 2026
    Stock
    EPA-DSY
    Action
    Reiterated: Sell
    Rating
    Sell
    Price target
    $16.00
  • Sep 25, 2026
    Stock
    EPA-DSY
    Action
    Reiterated: Sell
    Rating
    Sell
    Price target
    $16.00
  • Sep 23, 2026
    Stock
    ETR-NEM
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $72.00
  • Sep 22, 2026
    Stock
    SAP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $260.00
  • Sep 22, 2026
    Stock
    ETR-SAP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $220.00
  • Sep 21, 2026
    Stock
    LON-BYIT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $450.00
  • Sep 17, 2026
    Stock
    LON-SCT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $1700.00
  • Sep 17, 2026
    Stock
    LON-BYIT
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $370.00
  • Sep 8, 2026
    Stock
    LON-CCC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $6500.00

Charles’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Oct 20, 2026; ranking updated Oct 21, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Charles Brennan’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Charles Brennan ranks #772 of 1,121 with a 4.7★ rating. 52.4% of price targets were reached over a 7-year lookback (all analysts: 53.6%), and 100.0% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Charles Brennan’s success rate is 62.3% by the ranking source and 52.4% by Exent’s price-target hit-rate backtest, with a median of 99 days to reach a target.

Charles Brennan (Jefferies) covers 25 stocks, mostly in technology. The most frequently rated are EPA-DSY, ETR-SAP, EPA-CAP, BME-AMS, LON-CCC.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.